EIT RawMaterials: Leading Science Founder Urges Innovation Transformation at Universities in Fight Against Climate Change
14.9.2022 15:56:00 EEST | Business Wire | Press release
A leading innovator in science has urged European universities and higher education institutions to revolutionise their innovation activities to effectively tackle climate change. Dr. Riam Kanso, founder and CEO of Conception X, will be the keynote speaker at the INNOVEIT Stockholm: Innovation in Higher Education on 15 September. The event is coordinated and led by EIT RawMaterials, the world’s largest consortium on raw materials, funded by the European Institute of Innovation and Technology (EIT), a body of the European Union.
The registration for in-person or virtual attendance at INNOVEIT Stockholm is now open.
Reaching net-zero carbon emissions by 2050 means new innovations in technology and energy are urgently needed. These innovations will largely stem from universities and higher education institutions. The EIT Higher Education Institutions Initiative (EIT HEI) funds and supports higher education institutions in growing their research and development faculties and boosting entrepreneurship activities and synergies with industry players, many with the aim of accelerating deep tech and energy innovations coming to market (start-ups and spin-offs).
The EIT HEI Initiative is titled ‘Innovation Capacity Building for Higher Education’ and is a unique model that brings together industry/businesses with researchers and higher education. The initiative is a key objective for the EIT as part of the EIT’s new seven-year strategy for 2021-2027. The programme supports higher education institutions with expertise and coaching, access to the EIT innovation ecosystem, and funding to boost the capacity for innovation and entrepreneurship activities at European higher education institutions.
Dr. Kanso: Urgent Progress Needed for Innovation in Higher Education
Dr. Kanso’s company, Conception X, has a complementary mission to the EIT HEI Initiative. Conception X is an independent, non-profit that works closely with more than 30 universities across the UK to discover and train aspiring PhD founders from leading research labs, helping them become eligible for innovation grants, awards, and venture capital funding. Through a nine-month deep-tech venture programme, PhD students explore ways to commercialise their research while still at university – much like the EIT-Labelled Masters and PhD programmes.
Dr. Kanso says new models like this are needed to unleash Europe’s potential as a hotspot for meaningful innovation, especially with the continent’s 2050 deadline to reach net-zero emissions fast approaching.
Dr. Kanso said: “Universities and higher education institutions are built to spread knowledge that improves the world. Yet, the current system of spreading this knowledge by publishing papers can sometimes hinder progress – by the time a paper is published, the research could be three years old. We need to create models where research and innovation come together to reinforce and advance each other.”
EIT RawMaterials CEO Bernd Schäfer stressed: “Europe is at an epochal turning point, where the ambitious goals of the European Green Deal are placing more extraordinary demands on higher education than ever before. Our EIT HEI Initiative was established for this reason, to empower higher education institutions to become engines of innovation and foster sustainable growth and jobs. The initiative brings Europe’s education, research, and industry leaders together to work on strengthened innovation in higher education with the aim of solving some of the world’s biggest problems - like climate change.”
Speaking about the EIT HEI Initiative, Dr. Kanso said: “We’re working to promote knowledge and innovation and help great people excel. The more allies we have and the more connected we are, the easier it will be to achieve that. Network initiatives like the EIT HEI are crucial.’’
INNOVEIT: Stockholm - Focus on Innovation in Higher Education
This hybrid event will highlight the ongoing work of the EIT’s HEI Initiative. Discussions will focus on how the EIT HEI Initiative will connect with deep tech innovations and talents and EIT-Labelled education programmes for enhanced innovation capacity building.
All active projects selected for both the EIT HEI’s Cohort 1 (launched in July 2021) and Cohort 2 (launched in July 2022) will be present at the event. There are 23 active Cohort 1 and 26 active Cohort 2 projects in the HEI Initiative network. Cohort 1 projects will share the good practices and methodologies they have learned so far for increasing innovation capacity in European higher education institutions.
Dr. Tamer Abu-Alam is the Project Coordinator of one of EIT HEI Initiative’s funded Cohort 1 projects, CloudEARTHi, and an academic at UiT, the Artic University of Norway.
Dr. Abu-Alam says initiatives like the EIT HEI Initiative, and this event, are crucial because Europe can only be decarbonised if industry, research, and higher education work closely together.
‘’Without this coming together of stakeholders we cannot achieve a solution to the climate crisis. We are all working on the same problem - but from different perspectives. This is why the EIT HEI and the Stockholm event are so important - because everyone is brought together, everyone presents their point of view, and based on this we can innovate and work together to address this challenge.”
The CloudEARTHi project guides students on how to develop their business plan in line with the European Green Deal, and how to use big data to address gaps in their business model. Within just two months, one student has already started his own business to recycle computer components – an activity that will help to provide the EU with specific raw materials necessary for the green transition.
Dr. Tamer Abu-Alam will also take part in the panel discussion ‘EIT HEI Initiative: Innovation capacity building good practices.’
The event is an integral part of the INNOVEIT WEEKS, a series of events showcasing how EIT, Europe’s largest innovation ecosystem, offers unique opportunities to innovators and entrepreneurs, powering solutions to global challenges.
The registration for in-person or virtual attendance at INNOVEIT Stockholm is now open.
ENDS
Notes for the Editor
European Institute of Innovation and Technology (EIT)
The EIT is an EU body and an integral part of Horizon Europe, the EU Framework Programme for Research and Innovation. The Institute supports dynamic pan-European partnerships, EIT Knowledge and Innovation Communities, among leading companies, research labs, and universities. The EIT is Europe’s largest innovation ecosystem bringing together close to 3 000 partners from top business, research and education organisations across Europe in 200+ hubs. More than 3 800 students have graduated from EIT labelled master and doctoral programmes and over 100 000 have participated in EIT Community entrepreneurial trainings.
EIT HEI Initiative: Innovation Capacity Building for Higher Education
The EIT HEI Initiative: Innovation Capacity Building for Higher Education is a joint EIT Community programme led by EIT RawMaterials − one of the EIT’s Knowledge and Innovation Communities. The initiative aims to support higher education institutions with expertise and coaching, access to the EIT innovation ecosystem, and funding, enabling them to develop innovation action plans contextualised to the needs of individual higher education institutions. In July 2021, 23 projects started their activities after the EIT HEI Initiative Pilot Call. By 2027, the EIT HEI Initiative aims to support 550 higher education institutions boosting European innovation in higher education and driving the twin transition towards a more sustainable, digital and competitive Europe.
EIT RawMaterials
The objective of EIT RawMaterials is to secure a sustainable raw materials supply by driving innovation, education, and entrepreneurship across European industrial ecosystems. EIT RawMaterials provides a collaborative environment for disruptive and breakthrough innovations by connecting business with academia, research, and investment. It also invests in future generations of innovators for the raw materials sector, through initiatives ranging from the education of school students to higher qualifications for industry professionals.
The company is committed to supporting Europe’s transition towards a circular, green, and digital economy whilst strengthening its global competitiveness and securing employment. On this foundation, EIT RawMaterials has been mandated by the European Commission to lead and manage the European Raw Materials Alliance (ERMA).
EIT RawMaterials – developing raw materials into a major strength for Europe. Connecting Matters!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005543/en/
Contact information
EIT RawMaterials
Vanessa Lorenz, Head of Communications
E: vanessa.lorenz@eitrawmaterials.eu
M: + 49 174 2714312
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom